Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

46.51 -1.95 (-4.02%)
Official Closing Price Updated: 7:00 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price target. 
Via Benzinga
This House of Representative Just Bought Up To $95K In Novo Nordisk Stock
 
Via Benzinga
Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other... 
Via Benzinga
Topics Artificial Intelligence
Robbins LLP Urges NVO Stockholders with Large Losses to Contact the Firm for Information about Leading the Class Action Against Novo Nordisk A/S
From Robbins LLP
Via GlobeNewswire
Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India
Eli Lilly will raise Mounjaro's UK price by 170% in September while launching its Kwikpen injector in India, intensifying competition with Novo Nordisk in the global obesity drug market. 
Via Benzinga
3 Absurdly Cheap Stocks That Haven't Been Trading This Low in Years
These stocks are all down more than 30% this year and could prove to be bargain buys for long-term investors. 
Via The Motley Fool
Topics World Trade
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Levi &amp; Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Best Stock to Buy: Novo Nordisk Stock vs. UnitedHealth Stock
Healthcare stocks are underperforming this year due to unfavorable government policy. 
Via The Motley Fool
Why Novo Nordisk Stock Topped the Market Today
Bullishness slowly seems to be coming back to the beleaguered drugmaker. 
Via The Motley Fool
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Why Eli Lilly Stock Popped Today
The GLP-1 weight loss wars have gone global. 
Via The Motley Fool
Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens
Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs. 
Via Benzinga
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment
Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines – NVO
From Pomerantz LLP
Via GlobeNewswire
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
The 3 Things That Matter for Viking Therapeutics Now
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations. 
Via The Motley Fool
September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
September 30, 2025 Deadline: Contact Levi &amp; Korsinsky to Join Class Action Suit Against NVO
Via TheNewswire.com
Topics Fraud Lawsuit
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now
Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases. 
Via Benzinga
Topics Lawsuit
UK Government, Eli Lilly Partner To Target Obesity Health Gaps
A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and pharmacy-based services by summer 2026. 
Via Benzinga
Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock
Investors have a tough choice between these two excellent companies. 
Via The Motley Fool
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Strong Value Investment with Undervalued Potential
NOVO-NORDISK (NVO) is a top value stock with strong fundamentals, undervalued metrics, high profitability, and steady growth in diabetes & obesity care markets. 
Via Chartmill
Novo Nordisk Stock: Buy or Sell?
News from a competitor is increasing enthusiasm for Novo Nordisk stock. 
Via The Motley Fool
Is the Market Bullish or Bearish on Novo Nordisk?
 
Via Benzinga
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
Shareholders That lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.